The MAAPE score in intermediate and advanced hepatocellular carcinoma treated with Yttrium‐90 resin microsphere radioembolization

Abstract

Yttrium-90 resin microsphere radioembolization (RE) is not recommended for routine use in intermediate or advanced hepatocellular carcinoma (HCC) by recent guidelines. This study aims to establish pre-treatment variables which predict survival in HCC patients treated with RE to identify those who will benefit most from it, and to inform patient selection for future trials. Single center, retrospective study of consecutive patients with HCC treated with RE from 2007 to 2018. Patients included if undergoing their first RE treatment for intermediate or advanced HCC; a Child-Pugh score of B7 or less; and a performance status of 1 or less. Multivariable Cox regression identified variables that were significantly associated with survival. A predictive score was developed based upon coefficients from the fitted Cox regression model, and cubic spline regression was used to identify prognostic groups. One hundred thirteen patients with intermediate (53.1%) and advanced HCC (45.1%) followed for a median of 13.2months were included. Variables associated with superior survival used to derive the MAAPE score were lower Model for End-Stage Liver Disease score (≤7), lower Alpha-fetoprotein (≤150IU/L), higher serum Albumin (>37g/L), absence of Portal vein tumor thrombus, and better performance status (Eastern Cooperative Oncology Group=0). Three survival prognostic groups were identified: good (median overall survival 25.0months), average (15.3months), and poor (6.3months) (overall log-rank test, P<0.001). The MAAPE score accurately identifies HCC patients in whom RE is safe and effective. This will allow for optimal patient selection for future trials of RE versus systemic therapy.